Literature DB >> 2223424

Actions of zopiclone and carbamazepine, alone and in combination, on human skilled performance in laboratory and clinical tests.

T Kuitunen1, M J Mattila, T Seppälä, K Aranko, M E Mattila.   

Abstract

1. Possible interactions of zopiclone and carbamazepine on human skilled performance were studied in a randomized, double-blind, crossover trial with 12 healthy young subjects. 2. Psychomotor performance (coordination, reactions, attention, cognition) and subjective effects (VAS) were measured and venous blood sampled before and 1.5, 3, 4.5 and 6 h after single oral doses of placebo, 7.5 mg of zopiclone and 600 mg of carbamazepine, which were given alone or combined. Clinical test for drunkenness (CTD) was done 2 and 5 h after drug intake. 3. Both zopiclone and carbamazepine, when administered alone, impaired performance on laboratory tests, the decrements being recorded 1.5 to 6 h after intake. In line with the plasma concentrations, the zopiclone effects peaked earlier (at 1.5 h) and lasted for a shorter time than those of carbamazepine. Zopiclone had a more pronounced effect on perceptual and cognitive functions (digit substitution) and it affected extraocular muscle tone (Maddox wing), whereas carbamazepine had stronger effects on attention. Additive pharmacodynamic actions were found in most tests after the combined treatment with zopiclone and carbamazepine. 4. CTD proved to be less sensitive than the laboratory tests in revealing drug-induced decrement of performance after administration of one agent alone. However, it revealed the combined decremental effects of zopiclone and carbamazepine. 5. When the drugs were given together, the absorption of drugs was retarded. Carbamazepine-10,11-epoxide levels were lower after intake of the drug combination than those measured after intake of carbamazepine alone. 6. The results suggest that the clinical tests developed to detect alcohol effects do not necessarily reveal drug-induced impairment of performance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2223424      PMCID: PMC1368149          DOI: 10.1111/j.1365-2125.1990.tb03797.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  28 in total

1.  Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects-a review.

Authors:  J M Smith; H Misiak
Journal:  Psychopharmacologia       Date:  1976-05-28

2.  Effects of m-xylene on human equilibrium measured with a quantitative method.

Authors:  K Savolainen; M Linnavuo
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1979-04

3.  Anticonvulsant drug mechanisms of action.

Authors:  R L Macdonald; M J McLean; J H Skerritt
Journal:  Fed Proc       Date:  1985-07

4.  Pharmacological and clinical studies of cyclopyrrolones: zopiclone and suriclone.

Authors:  L Julou; J C Blanchard; J F Dreyfus
Journal:  Pharmacol Biochem Behav       Date:  1985-10       Impact factor: 3.533

5.  Lateral gaze nystagmus in carbamazepine-treated epileptic patients: correlation with total and free plasma concentrations of parent drug and its 10,11-epoxide metabolite.

Authors:  R Riva; M Contin; F Albani; E Perucca; G Ambrosetto; G Procaccianti; M Santucci; A Baruzzi
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

Review 6.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

7.  Measurement of recovery from outpatient general anaesthesia with a simple ocular test.

Authors:  J G Hannington-Kiff
Journal:  Br Med J       Date:  1970-07-18

8.  Effect of carbamazepine on psychomotor performance in näive subjects.

Authors:  G J MacPhee; C Goldie; D Roulston; L Potter; E Agnew; J Laidlaw; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Zopiclone produces effects on human performance similar to flurazepam, lormetazepam and triazolam.

Authors:  A N Griffiths; D M Jones; A Richens
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

10.  Residual effects of zopiclone and benzodiazepine hypnotics on psychomotor performance related to car driving.

Authors:  C Harrison; Z Subhan; I Hindmarch
Journal:  Drugs Exp Clin Res       Date:  1985
View more
  9 in total

Review 1.  The effects of fall-risk-increasing drugs on postural control: a literature review.

Authors:  Maartje H de Groot; Jos P C M van Campen; Marije A Moek; Linda R Tulner; Jos H Beijnen; Claudine J C Lamoth
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

Review 2.  Clinical management of patients with insomnia. The role of zopiclone.

Authors:  G Hajak; A Rodenbeck
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 3.  Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia.

Authors:  S Noble; H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

4.  Testing for benzodiazepine inebriation--relationship between benzodiazepine concentration and simple clinical tests for impairment in a sample of drugged drivers.

Authors:  Jørgen G Bramness; Svetlana Skurtveit; Jørg Mørland
Journal:  Eur J Clin Pharmacol       Date:  2003-09-20       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of zopiclone.

Authors:  C Fernandez; C Martin; F Gimenez; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

Review 6.  Clinically important drug interactions with zopiclone, zolpidem and zaleplon.

Authors:  Leah M Hesse; Lisa L von Moltke; David J Greenblatt
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 7.  The use of microcomputer-based psychomotor tests for the evaluation of benzodiazepine effects on human performance: a review with emphasis on temazepam.

Authors:  G W Kunsman; J E Manno; B R Manno; C M Kunsman; M A Przekop
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

8.  Suriclone enhances the actions of chlorpromazine on human psychomotor performance but not on memory or plasma prolactin in healthy subjects.

Authors:  M J Mattila; J Vanakoski; M E Mattila-Evenden; S L Karonen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 9.  Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic.

Authors:  A N Wadworth; D McTavish
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.